Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.

Abstract

Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram. Haloperidol in a dose of 3mgkg-1 p.o. prolonged the QT interval, but it did not induce torsade de pointes during the observation period of 21h (n=4), indicating that the dose would be safe. Meanwhile, haloperidol in a dose of 30mgkg-1 p.o. significantly increased the short-term variability in beat-to-beat analysis of QT interval (n=4), and it induced torsade de pointes in 4 animals out of 4, showing that the dose could be torsadogenic. Since 3mgkg-1 p.o. of haloperidol in this study can be estimated to provide about 8 times higher plasma concentrations than its therapeutic level, haloperidol may be used safely for most of the patients, as long as its plasma drug concentration is kept within the therapeutic range.